By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Endocyte, Inc. 

3000 Kent Avenue

West Lafayette  Indiana  47906  U.S.A.
Phone: 765-463-7175 Fax: 765-463-9271


Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer and other serious diseases. Endocyte uses its proprietary drug conjugation technology to create novel SMDCs and companion imaging agents for personalized targeted therapies. The company’s SMDCs actively target receptors that are over-expressed on diseased cells relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In addition, the company continues to pursue applications of the SMDC platform and is working to bring assets toward clinical development in several areas, including EC2629, its dual-targeted DNA crosslinker drug that can attack both TAMs and cancer cells, and its CAR T-Cell SMDC adaptor platform.

Key Statistics

Ownership: Public

Web Site: Endocyte
Symbol: ECYT

Company News
Endocyte (ECYT) Reports Second Quarter Financial Results And Provides Clinical And Pipeline Update 8/9/2017 1:51:46 PM
Endocyte (ECYT) Announces Second Quarter 2017 Earnings Conference Call 8/2/2017 1:43:39 PM
Stock Tanks as Endocyte (ECYT) Cuts 40% of Workforce, Slashes 2 Clinical Programs 6/2/2017 6:55:25 AM
Endocyte (ECYT) Reports First Quarter Financial Results And Provides Clinical And Pipeline Update 5/10/2017 10:08:01 AM
Endocyte (ECYT) Reports Fourth Quarter And Year End 2016 Financial Results And Provides Clinical And Pipeline Update 3/13/2017 10:29:42 AM
Endocyte (ECYT) And Seattle Children's Research Institute To Collaborate On Endocyte’s Small Molecule Drug Conjugate Bi-Specific Adaptor Molecules For CAR T-Cell Therapies 3/10/2017 9:01:23 AM
Endocyte (ECYT) Announces Fourth Quarter And Full Year 2016 Earnings Conference Call 3/2/2017 8:14:47 AM
Endocyte (ECYT) Appoints Michael T. Andriole As Chief Financial Officer 2/21/2017 10:44:51 AM
Endocyte (ECYT) Reports Third Quarter 2016 Financial Results 11/10/2016 1:54:39 PM
Endocyte (ECYT) Announces Third Quarter 2016 Earnings Conference Call 11/3/2016 11:07:39 AM